Does Wellpoint Cover Mounjaro? Rules, Costs, and Denials

Wellpoint does cover Mounjaro, but only on plans whose formulary lists it, only for type 2 diabetes, and only after prior authorization is approved. Coverage for weight loss alone is excluded across Wellpoint’s plans, and whether your specific plan includes tirzepatide depends on your state and line of business.

Diabetes Only, Not Weight Loss

The firmest rule across Wellpoint’s book of business is the indication. Mounjaro is approved for coverage when it is prescribed for type 2 diabetes. It is not approved when prescribed solely for weight management. A Wellpoint provider notice states that member benefits “specifically exclude weight loss drugs” and that GLP-1 receptor agonists “may not be approved” for that purpose.¹ The Iowa prior authorization document says requests for weight loss “will be denied.”²

Tirzepatide is sold under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Wellpoint’s pharmacy benefit manager, CarelonRx, notes that Mounjaro is “not indicated for weight loss.”³ Patients with both diabetes and obesity generally have a clearer path to coverage when the prescription is written for the diabetes indication.⁴

Coverage Varies by State and Plan

Wellpoint is a plan brand that runs Medicaid managed care, Medicare Advantage, and commercial products in different states, and each product has its own formulary. There is no single Wellpoint answer on Mounjaro.

Where it is clearly listed: Wellpoint’s Iowa Medicaid plan classifies Mounjaro as a “Preferred GLP-1 Receptor Agonist” with prior authorization required.² Washington’s Apple Health plan also covers GLP-1 agonists with prior authorization, though under stricter conditions described below.⁵

Where it is not on the preferred list: New Jersey’s Medicaid preferred drug list includes Ozempic and Trulicity but not Mounjaro or tirzepatide.⁶ Maryland’s list includes Ozempic, Trulicity, and Victoza but omits Mounjaro.⁷ In those states, members would need to request a formulary exception.

What Prior Authorization Requires

Even on plans that list Mounjaro, approval depends on clinical documentation. Based on Wellpoint’s own provider materials, these are the common requirements:

A documented type 2 diabetes diagnosis. Acceptable proof includes an HbA1c of 6.5% or higher, a fasting plasma glucose of 126 mg/dl or higher, a two-hour plasma glucose of 200 mg/dl or higher during an oral glucose tolerance test, or symptoms of hyperglycemia with a random plasma glucose of 200 mg/dl or higher.¹
Step therapy on some plans. Washington’s Apple Health plan requires a documented 90-day trial of metformin at the maximum tolerated dose and liraglutide at the maximum tolerated dose before approving another GLP-1. Washington also requires a qualifying comorbid condition such as chronic kidney disease, established cardiovascular disease, moderate to severe metabolic dysfunction-associated steatohepatitis, or moderate to severe obstructive sleep apnea.⁵
No concurrent DPP-4 inhibitor. Wellpoint’s Iowa plan will not approve a GLP-1 receptor agonist used at the same time as a DPP-4 inhibitor.²
Compliance with FDA labeling for age, dosing, contraindications, and precautions.

Step therapy for GLP-1 medications is common across insurers, and metformin is typically the first required trial before a brand-name agent is approved.⁸

How to Check Your Own Plan

Three practical ways to confirm whether your plan covers Mounjaro:

Log in to your Wellpoint account. Medicare and Medicaid members can see the formulary that applies to their plan and price specific drugs through the secure account.⁹
Search the online formulary for your state. Several states have a searchable tool where you can type “Mounjaro” or “tirzepatide” and see the tier, prior authorization status, and any quantity limits.¹⁰
Call Pharmacy Member Services at the number on the back of your Wellpoint ID card. A representative can confirm coverage, explain copay or coinsurance, and tell you whether step therapy applies.

If Coverage Is Denied

When a plan does not list Mounjaro, members or prescribers can request a formulary exception. In New Jersey, requests can be sent by email to submitmyexceptionreq@Wellpoint.com with a medical necessity justification.¹¹

Members can also appeal an adverse coverage decision within 180 calendar days. Pre-service appeals are generally resolved within 30 calendar days and post-service appeals within 60 days. Urgent cases qualify for an expedited appeal, which must be resolved within 72 hours.¹² If the internal appeal does not succeed, members can request an external review by an independent organization. That decision is binding on both the plan and the member, and Wellpoint covers the cost. Medicare members who exhaust Wellpoint’s process can also file a complaint directly with Medicare.¹³

Step therapy exceptions are possible when a patient has already tried the preferred medications on a prior plan, has documented allergies or side effects, or has a specific medical reason their prescriber can justify in writing.⁸

Cost Help from the Manufacturer

Members with commercial Wellpoint coverage may qualify for Eli Lilly’s Mounjaro Savings Card. If the commercial plan covers Mounjaro, the card can bring the cost down to as little as $25 per fill, with maximum annual savings up to $1,950. If the commercial plan does not cover it, the card can still reduce the price to $499 per month.¹⁴

The savings card is not available to anyone enrolled in Medicare, Medicaid, TRICARE, or VA programs. Because much of Wellpoint’s membership is on Medicaid or Medicare Advantage plans, those members cannot use the manufacturer discount and must rely on their plan’s formulary or the appeals process.¹⁴

Wellpoint Medicare Advantage

For Wellpoint Medicare Advantage members, Mounjaro can be covered under the Part D formulary when prescribed for type 2 diabetes, subject to the same prior authorization and step therapy rules. Federal law continues to prohibit Medicare Part D from covering drugs prescribed solely for weight loss.¹⁵

CMS launched the Medicare GLP-1 Bridge in July 2026, a temporary demonstration that covers certain GLP-1 medications for weight management outside the standard Part D benefit. The Bridge covers Wegovy and Zepbound, not Mounjaro. Patients with a Part D-covered indication such as type 2 diabetes are ineligible for the Bridge and must obtain their medication through the standard Part D formulary process.¹⁶

1
Wellpoint Provider News. Glucagon-Like Peptide-1 Prior Authorization Changes
2
Wellpoint Provider. Anti-Diabetic Non-Insulin Agents Prior Authorization
3
CarelonRx. GLP-1s and Weight Loss 101
4
Drugs.com. Mounjaro Covered Insurance Medicare
5
Wellpoint Provider. Prior Authorization: Antidiabetics — GLP-1 Agonists (Washington)
6
Wellpoint. New Jersey Medicaid-Approved Preferred Drug List
7
Wellpoint. Maryland Medicaid-Approved Preferred Drug List
8
Healthline. Mounjaro Step Therapy: What’s the Process to Get Coverage
9
Wellpoint. Drug List Formulary
10
Wellpoint. Maryland Medicaid Pharmacy Benefits
11
Wellpoint. New Jersey Medicaid Pharmacy
12
Wellpoint. Florida Complaints Grievances and Appeals
13
Wellpoint. Medicare Complaints Grievances
14
Eli Lilly. Mounjaro Savings Coverage
15
CMS. Medicare GLP-1 Bridge
16
CMS. Medicare GLP-1 Bridge Information for Part D Plans